Bioxyne, (ASX:BXN) through its subsidiary Breathe Life Sciences, has secured a two-year AU$50 million agreement with German pharmaceutical firm ADREXpharma to supply Good Manufacturing Practice (GMP)-produced medicinal cannabis products into Germany, according to a Tuesday filing with the Australian bourse.
The agreement includes a minimum purchase commitment of AU$25 million within the first 12 months, offering near-term revenue visibility, and will automatically renew for another 12-month term, per the filing.
The agreement extends an existing partnership, strengthening the company's position in Germany and supporting its expansion of GMP-certified production and regulated pharmaceutical supply across Europe, the filing added.